tiprankstipranks
Sangamo Therapeutics Seeks Court Approval for Stock Amendment
Company Announcements

Sangamo Therapeutics Seeks Court Approval for Stock Amendment

Don't Miss our Black Friday Offers:

An update from Sangamo Biosciences ( (SGMO) ) is now available.

Facing a class action complaint challenging the validity of their Common Stock Increase Amendment, Sangamo Therapeutics, Inc. sought validation from the Delaware Court of Chancery to solidify the increase of authorized common stock shares from 640,000,000 to 960,000,000. The complaint arose from a discrepancy over voting standards, alleging the company should have used a majority-of-outstanding-shares standard instead of a majority-of-votes-cast standard. To quell uncertainties and potential harm, the company took legal action to confirm the amendment’s effectiveness, adhering to new Delaware General Corporation Law provisions designed to streamline shareholder approval processes for corporate actions.

See more insights into SGMO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyClosing Bell Movers: Keysight up 9% after Q4 earnings beat
TheFlySangamo gets FDA clearance of IND application for ST-503 in iSFN
TheFlySangamo up 11% at $2.17 on FDA clearing IND for ST-503
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App